Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Zhaohong Wang, Hui Chen, Jingjing Chen, Zhong Hong, Yi Liao, Qiyu Zhang & Hongfei Tong. (2019) Emodin sensitizes human pancreatic cancer cells to EGFR inhibitor through suppressing Stat3 signaling pathway. Cancer Management and Research 11, pages 8463-8473.
Read now
Read now
Rodney Luwor, Andrew P. Morokoff, Stephanie Amiridis, Giovanna D’Abaco, Lucia Paradiso, Stanley S. Stylli, Hong P. T. Nguyen, Mark Tarleton, Kelly A. Young, Terence J. O’Brien, Phillip J. Robinson, Megan Chircop, Adam McCluskey & Nigel C. Jones. (2019) Targeting Glioma Stem Cells by Functional Inhibition of Dynamin 2: A Novel Treatment Strategy for Glioblastoma. Cancer Investigation 37:3, pages 144-155.
Read now
Read now
Fei Xue, Yanhui Liu, Hongwei Zhang, Yu Wen, Lei Yan, Qiang Tang, Erhui Xiao & Dongyi Zhang. (2016) Let-7a enhances the sensitivity of hepatocellular carcinoma cells to cetuximab by regulating STAT3 expression. OncoTargets and Therapy 9, pages 7253-7261.
Read now
Read now
Jianda Zhou, Rui Liu, Chengqun Luo, Xiao Zhou, Kun Xia, Xiang Chen, Ming Zhou, Qiong Zou, Peiguo Cao & Ke Cao. (2014) MiR-20a inhibits cutaneous squamous cell carcinoma metastasis and proliferation by directly targeting LIMK1. Cancer Biology & Therapy 15:10, pages 1340-1349.
Read now
Read now
Articles from other publishers (21)
Junyi Ren, Bo Wang, Qifeng Wu & Guiling Wang. (2022) Combination of niclosamide and current therapies to overcome resistance for cancer: New frontiers for an old drug. Biomedicine & Pharmacotherapy 155, pages 113789.
Crossref
Crossref
Deepak Vangala, Swetlana Ladigan, Sven T. Liffers, Soha Noseir, Abdelouahid Maghnouj, Tina-Maria Götze, Berlinda Verdoodt, Susanne Klein-Scory, Laura Godfrey, Martina K. Zowada, Mario Huerta, Daniel L. Edelstein, Jaime Martinez de Villarreal, Miriam Marqués, Jörg Kumbrink, Andreas Jung, Tobias Schiergens, Jens Werner, Volker Heinemann, Sebastian Stintzing, Doris Lindoerfer, Ulrich Mansmann, Michael Pohl, Christian Teschendorf, Christiane Bernhardt, Heiner Wolters, Josef Stern, Selami Usta, Richard Viebahn, Jacob Admard, Nicolas Casadei, Stefan Fröhling, Claudia R. Ball, Jens T. Siveke, Hanno Glimm, Andrea Tannapfel, Wolff Schmiegel & Stephan A. Hahn. (2021) Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models. Genome Medicine 13:1.
Crossref
Crossref
Wei Shi, Lintong Men, Xiu Pi, Tao Jiang, Dewei Peng, Shengqi Huo, Pengcheng Luo, Moran Wang, Junyi Guo, Yue Jiang, Lulu Peng, Li Lin, Sheng Li & Jiagao Lv. (2021) Shikonin suppresses colon cancer cell growth and exerts synergistic effects by regulating ADAM17 and the IL‑6/STAT3 signaling pathway. International Journal of Oncology 59:6.
Crossref
Crossref
Mouade El Bali, Joaira Bakkach & Mohcine Bennani Mechita. (2021) Colorectal Cancer: From Genetic Landscape to Targeted Therapy. Journal of Oncology 2021, pages 1-17.
Crossref
Crossref
Zoleykha Asadi, Mojtaba Fathi, Elham Rismani, Zahra Bigdelou & Behrooz Johari. (2021) Application of decoy oligodeoxynucleotides strategy for inhibition of cell growth and reduction of metastatic properties in nonresistant and erlotinib‐resistant SW480 cell line. Cell Biology International 45:5, pages 1001-1014.
Crossref
Crossref
Kaito Shibata, Takafumi Naito, Satoshi Hirakawa, Koji Suzuki, Seiji Hosokawa, Hiroyuki Mineta & Junichi Kawakami. (2021) Correlations between serum cetuximab and EGFR-related markers, and skin disorders in head and neck cancer patients. Cancer Chemotherapy and Pharmacology 87:4, pages 555-565.
Crossref
Crossref
Thu-Huyen Pham, Hyo-Min Park, Jinju Kim, Jin Tae Hong & Do-Young Yoon. (2020) STAT3 and p53: Dual Target for Cancer Therapy. Biomedicines 8:12, pages 637.
Crossref
Crossref
Mia M. Wu, Z. Zhang, Christy W.S. Tong, ViVi W. Yan, William C.S. Cho & Kenneth K.W. To. (2020) Repurposing of niclosamide as a STAT3 inhibitor to enhance the anticancer effect of chemotherapeutic drugs in treating colorectal cancer. Life Sciences 262, pages 118522.
Crossref
Crossref
Hiu Yee Kwan, Bin Liu, Chunhua Huang, Sarwat Fatima, Tao Su, Xiaoshan Zhao, Alan H. M. Ho, Quanbin Han, Xianjing Hu, Rui-Hong Gong, Minting Chen, Hoi Leong Xavier Wong & Zhaoxiang Bian. (2019) Signal transducer and activator of transcription-3 drives the high-fat diet-associated prostate cancer growth. Cell Death & Disease 10:9.
Crossref
Crossref
Winnie Fong & Kenneth K. W. To. (2019) Drug repurposing to overcome resistance to various therapies for colorectal cancer. Cellular and Molecular Life Sciences 76:17, pages 3383-3406.
Crossref
Crossref
Hui Xue, Ting Li, Pingzhang Wang, Xiaoning Mo, Hejun Zhang, Shigang Ding, Dalong Ma, Wenping Lv, Jing Zhang & Wenling Han. (2019) CMTM4 inhibits cell proliferation and migration via AKT, ERK1/2, and STAT3 pathway in colorectal cancer. Acta Biochimica et Biophysica Sinica 51:9, pages 915-924.
Crossref
Crossref
Mehdi Bouhaddou, Manon Eckhardt, Zun Zar Chi Naing, Minkyu Kim, Trey Ideker & Nevan J Krogan. (2019) Mapping the protein–protein and genetic interactions of cancer to guide precision medicine. Current Opinion in Genetics & Development 54, pages 110-117.
Crossref
Crossref
Fiona Tan, Tracy Putoczki, Jieqiong Lou, Elizabeth Hinde, Frédéric Hollande, Julie Giraud, Stanley Stylli, Lucia Paradiso, Hong-Jian Zhu, Oliver Sieber & Rodney Luwor. (2018) Ponatinib Inhibits Multiple Signaling Pathways Involved in STAT3 Signaling and Attenuates Colorectal Tumor Growth. Cancers 10:12, pages 526.
Crossref
Crossref
Elli Narvi, Katri Vaparanta, Anna Karrila, Deepankar Chakroborty, Sakari Knuutila, Arto Pulliainen, Maria Sundvall & Klaus Elenius. (2018) Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin. Scientific Reports 8:1.
Crossref
Crossref
Changhe Zhang, Hong Xu, Zhenping Zhou, Ye Tian, Xiaofei Cao, Guochang Cheng & Qinghong Liu. (2018) Blocking of the EGFR‑STAT3 signaling pathway through afatinib treatment inhibited the intrahepatic cholangiocarcinoma. Experimental and Therapeutic Medicine.
Crossref
Crossref
Ahmad A. Zulkifli, Fiona H. Tan, Tracy L. Putoczki, Stanley S. Stylli & Rodney B. Luwor. (2017) STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics. Molecular and Cellular Endocrinology 451, pages 15-23.
Crossref
Crossref
Susana G. Cárdenas-Ramos, Gregorio Alcázar-González, Luisa M. Reyes-Cortés, Abdiel A. Torres-Grimaldo, Ana L. Calderón-Garcidueñas, José Morales-Casas, Patricia Flores-Sánchez, Raúl De León-Escobedo, Antonio Gómez-Díaz, Carmen Moreno-Bringas, Jorge Sánchez-Guillén, Pedro Ramos-Salazar, César González-de León & Hugo A. Barrera-Saldaña. (2017) The Frequency and Type of K-RAS Mutations in Mexican Patients With Colorectal Cancer. American Journal of Clinical Oncology 40:3, pages 274-276.
Crossref
Crossref
Wen‑Xiang Li, Meng‑Xuan Yang, Xin‑Qiang Hong, Tian‑Geng Dong, Tuo Yi, Sheng‑Li Lin, Xin‑Yu Qin & Wei‑Xin Niu. (2016) Overexpression of gelsolin reduces the proliferation and invasion of colon carcinoma cells. Molecular Medicine Reports.
Crossref
Crossref
Janani Kumar. 2016. STAT Inhibitors in Cancer. STAT Inhibitors in Cancer
177
190
.
Uddalak Bharadwaj, Moses M. Kasembeli & David J. Tweardy. 2016. STAT Inhibitors in Cancer. STAT Inhibitors in Cancer
95
161
.
Xuan Liu, Qing Ji, Zhongze Fan & Qi Li. (2015) Cellular signaling pathways implicated in metastasis of colorectal cancer and the associated targeted agents. Future Oncology 11:21, pages 2911-2922.
Crossref
Crossref